BioXcel Therapeutics (BTAI) Assets Average (2018 - 2026)

BioXcel Therapeutics' Assets Average history runs 9 years deep, the most recent figure standing at $39.5 million for Q1 2026.

• In Q1 2026, Assets Average rose 2.65% year-over-year to $39.5 million; the TTM figure through Mar 2026 stood at $39.5 million (up 2.65% YoY), while the FY2025 annual figure was $41.6 million, down 25.69% from the prior year.
• Assets Average was $39.5 million for Q1 2026 at BioXcel Therapeutics, down from $44.9 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $246.5 million in Q3 2022 to a low of $32.2 million in Q2 2025.
• Historically, Assets Average has averaged $113.5 million across 5 years, with a median of $78.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Assets Average climbed 7.18% in 2022, then tumbled 61.36% in 2023.
• A 5-year view of Assets Average shows it stood at $225.3 million in 2022, then sank by 61.36% to $87.1 million in 2023, then tumbled by 49.91% to $43.6 million in 2024, then increased by 2.84% to $44.9 million in 2025, then slipped by 12.0% to $39.5 million in 2026.
• The last three Assets Average figures came in at $39.5 million (Q1 2026), $44.9 million (Q4 2025), and $35.3 million (Q3 2025), per Business Quant data.